Title: NDRG1 promotes growth of hepatocellular carcinoma cells by directly interacting with GSK-3beta and Nur77 to prevent beta-catenin degradation Lu WJ, Chua MS, Wei W, So SK Ref: Oncotarget, 6:29847, 2015 : PubMed
The N-myc downstream regulated gene 1 (NDRG1) is significantly associated with advanced tumor stages and poor survival of hepatocellular carcinoma (HCC), thereby implicating it as a potential target for HCC treatment. We aim to further understand its biological roles in hepatocarcinogenesis, as a means to exploit it for therapeutic purposes. By screening using the ProtoArray(R) Human Protein Microarrays, we identified glycogen synthase kinase 3beta (GSK-3beta) and the orphan nuclear receptor (Nur77) as potential interaction partners of NDRG1. These interactions were confirmed in HCC cell lines in vitro by co-immunoprecipitation; and co-localizations of NDRG1 with GSK-3beta and Nur77 were observed by immunofluorescence staining. Additionally, high levels of NDRG1 competitively bind to GSK-3beta and Nur77 to allow beta-catenin to escape degradation, with consequent elevated levels of downstream oncogenic genes. In vivo, we consistently observed that NDRG1 suppression in HCC xenografts decreased beta-catenin levels and its downstream target Cyclin D1, with concomitant tumor growth inhibition. Clinically, the over-expression of NDRG1 in HCC patient samples is positively correlated with GSK-3beta-9ser (| R | = 0.28, p = 0.01), Nur77 (| R | = 0.42, p < 0.001), and beta-catenin (| R |= 0.32, p = 0.003) expressions. In conclusion, we identified GSK-3beta and Nur77 as novel interaction partners of NDRG1. These protein-protein interactions regulate the turnover of beta-catenin and subsequent downstream signaling mediated by beta-catenin in HCC cells, and provides potential targets for future therapeutic interventions.
        
Related information
Citations formats
Lu WJ, Chua MS, Wei W, So SK (2015) NDRG1 promotes growth of hepatocellular carcinoma cells by directly interacting with GSK-3beta and Nur77 to prevent beta-catenin degradation Oncotarget6: 29847-59
Lu WJ, Chua MS, Wei W, So SK (2015) Oncotarget6: 29847-59